204 related articles for article (PubMed ID: 32167723)
1. Editorial Comment: Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.
Zequi SC
Int Braz J Urol; 2020; 46(3):476. PubMed ID: 32167723
[No Abstract] [Full Text] [Related]
2. Cytoreductive nephrectomy and exposure to sunitinib - a post hoc analysis of the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trial.
Abu-Ghanem Y; van Thienen JV; Blank C; Aarts MJB; Jewett M; de Jong IJ; Lattouf JB; van Melick HHE; Wood L; Mulders P; Rottey S; Wagstaff J; Zondervan P; Powles T; Neven A; Collette L; Tombal B; Haanen J; Bex A
BJU Int; 2022 Jul; 130(1):68-75. PubMed ID: 34706141
[TBL] [Abstract][Full Text] [Related]
3. Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME).
De Bruijn RE; Mulders P; Jewett MA; Wagstaff J; Van Thienen JV; Blank CU; Van Velthoven R; Wood L; van Melick HE; Aarts MJ; Lattouf JB; Powles T; De Jong IJ; Rottey S; Tombal B; Marreaud S; Collette S; Collette L; Haanen JB; Bex A
Eur Urol; 2019 Oct; 76(4):437-440. PubMed ID: 31227307
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.
Bex A; Mulders P; Jewett M; Wagstaff J; van Thienen JV; Blank CU; van Velthoven R; Del Pilar Laguna M; Wood L; van Melick HHE; Aarts MJ; Lattouf JB; Powles T; de Jong Md PhD IJ; Rottey S; Tombal B; Marreaud S; Collette S; Collette L; Haanen J
JAMA Oncol; 2019 Feb; 5(2):164-170. PubMed ID: 30543350
[TBL] [Abstract][Full Text] [Related]
5. The evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma.
Graham J; Bhindi B; Heng DYC
Curr Opin Urol; 2019 Sep; 29(5):507-512. PubMed ID: 31305275
[TBL] [Abstract][Full Text] [Related]
6. Cytoreductive Nephrectomy and Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives.
Napolitano L; Manfredi C; Cirillo L; Fusco GM; Passaro F; Abate M; La Rocca R; Mastrangelo F; Spirito L; Pandolfo SD; Crocetto F; Arcaniolo D; Barone B
Medicina (Kaunas); 2023 Apr; 59(4):. PubMed ID: 37109725
[TBL] [Abstract][Full Text] [Related]
7. Sunitinib and Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma.
Bajic P; Flanigan RC; Joyce CJ; Clark JI
J Urol; 2019 Mar; 201(3):453-454. PubMed ID: 30266335
[No Abstract] [Full Text] [Related]
8. Has the Age of Cytoreductive Nephrectomy Come to an End?: Commentary on: Sunitinib Alone or After Nephrectomy in Metastatic Renal-Cell Carcinoma.
Kesch C; Black PC
Urology; 2018 Nov; 121():1-2. PubMed ID: 30077538
[No Abstract] [Full Text] [Related]
9. Multicenter randomized trial of deferred cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma receiving checkpoint inhibitors: the NORDIC-SUN-Trial.
Iisager L; Ahrenfeldt J; Donskov F; Ljungberg B; Bex A; Lund L; Lyskjær I; Fristrup N
BMC Cancer; 2024 Feb; 24(1):260. PubMed ID: 38402173
[TBL] [Abstract][Full Text] [Related]
10. Re: Arnaud Méjean, Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. N Engl J Med 2018;379:417-27: CARMENA Trial: Is This the End of Cytoreductive Nephrectomy in Patients with Clear-cell Renal Cell Carcinoma?
Massari F; Di Nunno V; Santoni M
Eur Urol Oncol; 2019 May; 2(3):340-341. PubMed ID: 31200852
[No Abstract] [Full Text] [Related]
11. Surgical and focal treatment for metastatic renal cell carcinoma: A literature review.
Naito S; Kato T; Tsuchiya N
Int J Urol; 2022 Jun; 29(6):494-501. PubMed ID: 35340081
[TBL] [Abstract][Full Text] [Related]
12. Individualised Indications for Cytoreductive Nephrectomy: Which Criteria Define the Optimal Candidates?
Larcher A; Wallis CJD; Bex A; Blute ML; Ficarra V; Mejean A; Karam JA; Van Poppel H; Pal SK
Eur Urol Oncol; 2019 Jul; 2(4):365-378. PubMed ID: 31109902
[TBL] [Abstract][Full Text] [Related]
13. Cytoreductive nephrectomy in metastatic renal cancer - less is more.
Bex A; Haanen J
Nat Rev Clin Oncol; 2018 Oct; 15(10):595-596. PubMed ID: 29967447
[No Abstract] [Full Text] [Related]
14. Cytoreductive nephrectomy is dead, long live cytoreductive nephrectomy.
Capitanio U; Larcher A; Montorsi F
BJU Int; 2019 Jul; 124(1):6-7. PubMed ID: 30656818
[No Abstract] [Full Text] [Related]
15. Cytoreductive Nephrectomy in Metastatic Renal Cell Cancer: Not All That It's Cut Out to Be.
Lara PN; Evans CP
JAMA Oncol; 2019 Feb; 5(2):171-172. PubMed ID: 30543365
[No Abstract] [Full Text] [Related]
16. Reassessing the Role of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma in 2019.
Psutka SP; Chang SL; Cahn D; Uzzo RG; McGregor BA
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():276-283. PubMed ID: 31099657
[TBL] [Abstract][Full Text] [Related]
17. [CYTOREDUCTIVE NEPHRECTOMY IN METASTATIC RENAL CELL CANCER].
Nosov AK; Novik AV; Vorobiev AV; Samartseva EE; Reva SA; Baldueva IA; Lushina PA
Vopr Onkol; 2015; 61(3):494-8. PubMed ID: 26242167
[TBL] [Abstract][Full Text] [Related]
18. Impact of cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma receiving systemic tyrosine kinase inhibitor therapy: A multicenter retrospective study.
Hatakeyama S; Naito S; Numakura K; Kato R; Koguchi T; Kojima T; Kawasaki Y; Kandori S; Kawamura S; Tsushima E; Nishiyama H; Ito A; Kojima Y; Habuchi T; Obara W; Tsuchiya N; Ohyama C
Int J Urol; 2021 Apr; 28(4):369-375. PubMed ID: 33314387
[TBL] [Abstract][Full Text] [Related]
19. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma.
Bhindi B; Abel EJ; Albiges L; Bensalah K; Boorjian SA; Daneshmand S; Karam JA; Mason RJ; Powles T; Bex A
Eur Urol; 2019 Jan; 75(1):111-128. PubMed ID: 30467042
[TBL] [Abstract][Full Text] [Related]
20. Considerations for the Next Clinical Trial Evaluating the Role of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma.
Kim HL; Mayerson E; Lara PN; Messing E; Tangen C; Shuch BM; Vaishampayan U
Eur Urol Focus; 2019 Nov; 5(6):927-929. PubMed ID: 31103605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
